Objectives To compare the performance of traditional G-banding karyotyping with that of copy number variation sequencing (CNV-Seq

No abstract

ABSTRACT. We determined whether genetically engineered immature dendritic cells (imDCs) mediated by lentiviral vectors alleviate acute graft-versus-host disease (GVHD) after allogeneic bone marrow transplantation (allo-BMT) in mice. We introduced the mouse chemokine receptor 7 (Ccr7) gene into the bone marrowderived imDCs of C57BL/6 mice to construct genetically engineered imDCs. A 1:1 mixture of bone marrow and spleen cells from the donors was injected into the recipients, which were divided into four groups: radiation, transplantation, empty vector, and transgenic imDC groups. Symptoms, clinical scores, GVHD pathological changes, and survival times and rates of recipients were recorded; secretion of IFN-γ and IL- 11444-11455 (2015) 4, and allogeneic chimerism rates were detected. The survival time of the transgenic imDC group (27.5 ± 7.55 days) was significantly longer than in the other three groups (P < 0.01). The GVHD score of the imDC group mice was significantly lower than in the transplantation and empty vector groups (P < 0.05), which meant that mice in the transgenic imDC group had the lightest pathology damage in the target organs. In the transplantation group, IFN-γ increased while IL-4 decreased. In contrast, IFN-γ decreased and IL-4 increased in both empty vector and trans-imDC groups, and the difference was significant in the latter (P < 0.01). Thirty days or more following transplantation, the allogeneic chimerism rate was still 95-100%, suggesting complete donor type implantation. Ccr7 transfection into imDCs suppressed occurrence and severity of acute GVHD after allo-BMT in mice; the mechanism might be associated with IFN-γ decrease and IL-4 increase.

4122 For acute Lymphoblastic Leukemia(ALL), several cytogenetic aberrations have been shown to play a crucial role in clinical Prognosis and also are being used as targets for response to therapy. This has led to Cytogenetics, and more recently Fluorescence In Situ ybridization(FISH), to be a tool for the detection of ALL treatment trials. Conventional cytogenetic(CC) analysis is a technically demanding and time-consuming process that is hindered by the limited availability of informative metaphase cells. Thus, interphase FISH is often used to complement CC,rule out submicroscopic rearrangements, and evaluate specimens with poor morphology or no growth in culture. The Chromoprobe Multiprobe ALL panel (Cytocell Technologies,Cambridge, UK) has been designed to detect rearrangements that occur primarily in B-cell lineage ALL, and includ some T-lineage markers. This panel detect the rearrangements of MYC, E2A, MLL, IGH, and p16; fusions of BCR/ABL and TEL/AML1 simultaneously; enumeration of chromosomes 4, 10, and 17 Probes for the specific rearrangements can also be used to assess ploidy. In this study, we performed the multi-probe FISH assay on interphase cells to detect multiple abnormalities associated with adult ALL.At prensent, We analyzed 48 samples from ALL cases using a FISH panel,the results showed that 71% cases had 1 or more genetic abnormalities. The most frequent abnormality was BCR/ABL, followed by MLL, IGH abnormalities, MYC rearrangement, TEL/AML1 fusion, +10, p16, 8 cases had MLL with IGH abnormalities and TEL/AML1 fusion, 7 cases had BCR/ABL fusion with MYC rearrangement,3cases had MLL and p16, no fusion partner was detected in 14 cases. Meanwhile,detected this samples with CC,we found that 42% cases had chromosome abnormalities,and 16% samples without growth in culture. This reults preliminary demonstrated that ALL always with multiple karyotype abnormalities, Multiprobe FISH is an essential method to refine the cytogenetic analysis. This study is going on,further study including more samples was necessary. Disclosures: No relevant conflicts of interest to declare.